English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical: The NDA of the New Drug, independently developed for the treatment of advanced breast cancer was accepted by NMPA
Oct 17, 2023 16:01 HKT
四环医药入选2023中国医药创新企业100强榜单「第一梯级企业」
Oct 13, 2023 18:09 HKT
四環醫藥入選2023中國醫藥創新企業100強榜單「第一梯級企業」
Oct 13, 2023 18:08 HKT
Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023
Oct 13, 2023 18:07 HKT
A closer examination at JinMed's top-line growth trajectory, revealing an abundance growth potential
Oct 10, 2023 20:12 HKT
ACROMETA's Life Science Incubator (LSI) Signs Agreement with Ho Bee Land subsidiary to operate Co-Working Laboratory
Oct 06, 2023 17:30 HKT
復星和諾貝爾獎的緣分
Oct 05, 2023 17:12 HKT
The Story of Fosun and the Nobel Prize
Oct 05, 2023 17:11 HKT
ZeptoMetrix Awarded in Vitro Diagnostic Regulation (IVDR) Certification
Oct 03, 2023 21:00 HKT
HanchorBio Announces First Patient Dosed in the Phase 1 Multi-Regional Clinical Trial of HCB101
Oct 03, 2023 19:30 HKT
绿竹生物核心产品重组带状疱疹疫苗LZ901于中国启动III期临床试验
Sep 29, 2023 10:31 HKT
綠竹生物核心產品重組帶狀皰疹疫苗LZ901於中國啟動III期臨床試驗
Sep 29, 2023 10:30 HKT
綠竹生物(02480.HK):重組帶狀皰疹疫苗LZ901啟動三期臨床研究 帶狀皰疹疫苗市場競爭迎新曙光
Sep 29, 2023 10:23 HKT
绿竹生物(02480.HK):重组带状疱疹疫苗LZ901启动三期临床研究 带状疱疹疫苗市场竞争迎新曙光
Sep 29, 2023 10:22 HKT
Hyris Supports Researchers and Developers to Launch Testing Kits via New Onboarding Programs
Sep 27, 2023 17:00 HKT
致力于开发中国双抗疗法的生物技术公司武汉友芝友生物于香港联交所主板正式挂牌
Sep 25, 2023 12:47 HKT
致力於開發中國雙抗療法的生物技術公司武漢友芝友生物於香港聯交所主板正式掛牌
Sep 25, 2023 12:46 HKT
A biotechnology company dedicated to developing BsAb-based therapies in China, YZY Biopharma Officially Listed on Main Board of SEHK

Sep 25, 2023 12:45 HKT
Sirnaomics集团入驻香港科学园 共创香港生物医药发展新篇章
Sep 21, 2023 16:49 HKT
Sirnaomics集團入駐香港科學園 共創香港生物醫藥發展新篇章
Sep 21, 2023 16:48 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: